MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-21-2026
So-Young International Balance Sheet 2011-2026 | SY
Annual Balance Sheet So-Young International
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -563 M | -441 M | - | - | - | - | - | - | |||
Long Term Debt Current |
- | - | - | - | 39.5 M | 37.8 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
146 M | 113 M | 52 M | 101 M | 102 M | 121 M | - | 594 M | - | - | - | - | - | - |
Total Current Liabilities |
630 M | 540 M | 538 M | 712 M | 571 M | 467 M | 302 M | - | - | - | - | - | - | - |
Total Liabilities |
776 M | 653 M | 590 M | 813 M | 672 M | 587 M | 302 M | 735 M | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | 135 M | - | - | 57.2 M | - | - | - | - | - | - |
Retained Earnings |
-926 M | -330 M | -347 M | -272 M | -254 M | -259 M | -394 M | -169 M | - | - | - | - | - | - |
Total Assets |
2.74 B | 3.21 B | 3.2 B | 3.33 B | 3.29 B | 3.23 B | 1.34 B | 568 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | - | 1.13 B | 885 M | 563 M | 441 M | - | - | - | - | - | - |
Book Value |
1.96 B | 2.56 B | 2.61 B | 2.52 B | 2.62 B | 2.64 B | 1.04 B | -167 M | - | - | - | - | - | - |
Total Shareholders Equity |
1.84 B | 2.44 B | 2.61 B | 2.52 B | 2.6 B | 2.64 B | -358 M | -167 M | - | - | - | - | - | - |
All numbers in CNY currency
Quarterly Balance Sheet So-Young International
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | 62.4 M | - | - | - | 93 M | - | - | - | 121 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 101 M | - | - | - | 102 M | - | - | - | 121 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | 813 M | - | - | - | 672 M | - | - | - | 587 M | - | - | - | 302 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | 139 M | - | - | - | 135 M | - | - | - | 93.7 M | - | - | - | 117 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | - | -272 M | - | - | - | -254 M | - | - | - | -259 M | - | - | - | -394 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | - | - | 3.33 B | - | - | - | 3.29 B | - | - | - | 3.23 B | - | - | - | 1.34 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | - | 1.33 B | - | - | - | 1.13 B | - | - | - | 885 M | - | - | - | 563 M | - | - | - | 441 M | - | - | - | 18.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | - | - | 2.52 B | - | - | - | 2.62 B | - | - | - | 2.64 B | - | - | - | 1.04 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | - | - | 2.45 B | - | - | - | 2.6 B | - | - | - | 2.64 B | - | - | - | -358 M | - | - | - | -167 M | - | - | - | -156 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CNY currency
Balance Sheet is a fundamental financial report of So-Young International , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
American Well Corporation
AMWL
|
$ 5.5 | -0.18 % | $ 88.3 M |  USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
HealthStream
HSTM
|
$ 22.03 | -0.09 % | $ 669 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
Evolent Health
EVH
|
$ 3.39 | -4.51 % | $ 318 M | USA |
 |
HealthEquity
HQY
|
$ 81.24 | 0.11 % | $ 6.95 B | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Omnicell
OMCL
|
$ 41.86 | 0.79 % | $ 1.93 B | USA |
 |
GoodRx Holdings
GDRX
|
$ 2.29 | 4.82 % | $ 883 M | USA |
 |
Health Catalyst
HCAT
|
$ 1.88 | -3.85 % | $ 113 M | USA |
 |
Progyny
PGNY
|
$ 17.38 | -2.3 % | $ 1.49 B | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Teladoc Health
TDOC
|
$ 5.09 | -0.78 % | $ 897 M | USA |
 |
10x Genomics
TXG
|
$ 22.22 | -0.67 % | $ 2.6 B | USA |
 |
Veeva Systems
VEEV
|
$ 194.62 | 3.26 % | $ 31.2 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
SCWorx Corp.
WORX
|
$ 0.13 | -4.17 % | $ 190 K | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 7.74 | -1.65 % | $ 133 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Phreesia
PHR
|
$ 12.35 | -2.22 % | $ 674 M | USA |
 |
Schrödinger
SDGR
|
$ 12.84 | -2.13 % | $ 943 M | USA |
 |
Zhongchao
ZCMD
|
$ 1.67 | 0.03 % | $ 8.69 M |  China |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |